September 24, 2018
OICR takes part in international multicentre study to standardize promising breast cancer digital pathology test
The Ki67 immunohistochemistry assay is a test that can help evaluate the aggressiveness of breast tumours, predict disease outcomes, monitor cancer progression and identify patients who are more likely to respond to a given therapy. Despite its potential to help patients with breast cancer, the analysis of Ki67 has not been widely adopted in the clinic, mostly due to the lack of standardization across laboratories.
July 31, 2018
Cheryl Crozier talks about her work in OICR’s Diagnostic Development team and how it could help doctors make a difference in treating cancer patients.
June 4, 2018
Current HER2 tests help predict which breast cancer patients will respond to HER2-targeted therapies, but sometimes these tests provide unclear results. An Expert Panel of pathologists and cancer researchers, including Dr. John Bartlett from OICR, recently published revised clinical practice guidelines for HER2 testing in breast cancer to help improve clarity of HER2 test results.
January 12, 2018
Endocrine therapy uses hormone antagonists to greatly reduce the risk of disease recurrence in women with early-stage, estrogen-receptor (ER) positive breast cancer. However, the treatment can come with severe side effects. Around 30 per cent of women stop taking the therapy after three years largely due to these negative impacts. Usually patients receive the hormone therapy for five years following initial treatment (e.g., chemotherapy, surgery), but it can also be taken longer-term. A central question facing patients and clinicians is how to balance, in their decision making, the side effects of long-term treatment with the potential reduction in recurrence risk. In short, they want to know: ‘is it worth it?’
September 6, 2017
OICR’s Tissue Portal is a new central entry and exit point for human tissue derived samples handled at OICR. This will serve as a gateway for tissue-based research projects to access over 100 services and resources at OICR being made available through the OICR Collaborative Research Resources on a cost-sharing basis. The Tissue Portal will standardize and streamline the storage, processing and distribution of samples for collaborative research studies at OICR.
April 13, 2017
Breast cancer is the most common form of cancer amongst women in Canada and worldwide, but despite its prevalence, a group of researchers believes that it should often be treated as a rare disease. Doing so would change clinical approaches and improve treatment for patients.
September 19, 2016
Dr. Rebecca Tamarchak discusses the launch of OICR’s new Collaborative Research Resources Directory, how it works, and plans for its development in the future.
Over the past decade, OICR has established state-of-the-art Technology Programs in molecular pathology and diagnostic development, genomics, informatics, medicinal chemistry and imaging, which are translating promising cancer discoveries into products, services and policies that improve cancer prevention and care for patients.
July 26, 2016
OICR is making its technology infrastructure, expertise and resources more available to the Ontario cancer community
Technology platforms are often one of the biggest enablers of high-impact research. Since it was established in 2005, OICR has invested in developing technology infrastructure, expertise and resources in diagnostic development, genomics, imaging, informatics and medicinal chemistry. These clusters consist of research and technical experts and state-of-the-art equipment.